SECsense Logo

Sunshine Biopharma Inc. 8-K Report: Key Updates for Investors (Jan 2025)

$SBFM
Form 8-K
Filed on: 2025-01-15
Source
Sunshine Biopharma Inc. 8-K Report: Key Updates for Investors (Jan 2025)

Based on the provided XML section from the financial report, here are the key insights extracted:

  1. Entity Information:
  • Company Name: Sunshine Biopharma Inc.
  • CIK (Central Index Key): 0001402328
  • SEC File Number: 001-41282
  • Tax ID: 20-5566275
  • Address: 333 Las Olas Way CU4 Suite 433, Fort Lauderdale, FL 33301
  • Contact Number: (954) 330-0684
  1. Report Type:
  • This filing is an 8-K report, indicating that it is a current report to announce major events that shareholders should know about.
  1. Relevant Dates:
  • As of Date: January 13, 2025
  • Reporting Period: The report covers the same date, January 13, 2025.
  1. Stock Information:
  • Common Stock:
    • Par Value: $0.001
    • Ticker Symbol: SBFM (NASDAQ)
  • Common Stock Purchase Warrants:
    • Ticker Symbol: SBFMW (NASDAQ)
  1. Measurement Units:
  • Financial measures are reported in USD and shares.
  1. Stock Classes:
  • The report includes explicit references to two classes of stock:
    • Common Stock
    • Common Stock Purchase Warrants
  1. Context and Segmentation:
  • The report specifies contexts for financial reporting, indicating that it discusses both common stock and common stock purchase warrants under distinct segments.

Insights:

  • Sunshine Biopharma is actively reporting on its common stock and related financial instruments, suggesting ongoing corporate actions or developments that could be significant for investors.
  • The specifics of the report could relate to stock performance, issuance of new shares, or warrant offerings, which may influence the company’s market valuation and investor interest.
  • The filing is timely and relevant, given its date of January 13, 2025, pointing to a need for stakeholders to be aware of current corporate events.

This information should provide stakeholders, analysts, and investors with a comprehensive understanding of Sunshine Biopharma's current financial reporting status and its securities.